Pfizer CEO Albert Bourla joins The Exchange to discuss new developments with his company’s Covid vaccine, one of the two mRNA vaccines approved for emergency use in the U.S. The company is reporting new data about waning immunity and protection against severe disease six months after getting the shot. Because of this, the company hopes for FDA emergency authorization for a booster dose. “They take the data very seriously,” Bourla says about the FDA emergency authorization approval process. To see the full interview with Bourla sign up for a free trial to CNBC Pro:
» Subscribe to CNBC TV:
» Subscribe to CNBC:
» Subscribe to CNBC Classic:
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:
Connect with CNBC News Online
Get the latest news:
Follow CNBC on LinkedIn:
Follow CNBC News on Facebook:
Follow CNBC News on Twitter:
Follow CNBC News on Instagram:
#CNBC
#CNBCTV
